| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | ||
| Financial Indicators | ||
|---|---|---|
| Market Cap | 16.45 Cr. | |
| Earnings per share (EPS) | 2.44 | Trailing Twelve Months Ending 2021-03 |
| Price-Earning Ratio (PE) | 15.18 | Trailing Twelve Months Ending 2021-03 |
| Industry PE | 35.17 | Trailing Twelve Months Ending 2021-03 |
| Book Value / Share | 28.29 | Trailing Twelve Months Ending 2021-03 |
| Price to Book Value | 1.31 | Calculated using Price: 37.05 |
| Dividend Yield | 0.00 | Period Ending 2020-03 |
| No. of Shares Subscribed | 0.44 Cr. | 4,440,568 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
Link Pharma Chem, incorporated on December 28, 1984 is a manufacturer of thionyl chloride. The company manufactures thionyl chloride and other inorganic chemical intermediates at its plants located in the Baroda and Ankleshwar districts of Gujarat with an installed capacity of 2,100 TPA. In FY08, the company received an international grant from United Nations Industrial Development Organization of Rs 7.7 million for phasing out a carbon tetra chloride product as raw material, which was implemented. The company plans to develop the acquired land in the Baroda district and has purchased a 10,800 sq. m. plot with RCC building of approximately 50,000 sq. ft. constructed area from DRT Ahmedabad for Rs 14 million for diversification projects. Link Pharma Chem has, over the years, followed the best business practices. The company believes that good corporate governance is essential to achieve long-term corporate goals and to enhance stakeholders' value. In this pursuit, the company is committed to conducting business in accordance with the highest legal and ethical standard, superior product quality and services to its customers. All employees are bound by a code of conduct, which sets forth the company's policies on important issues, including relationship with customers, vendors and the government. Business areas of the company: The company manufactures thionyl chloride and other inorganic chemical intermediates at its plants located in the Baroda and Ankleshwar districts of Gujarat with an installed capacity of 2,100 TPA. |
||
Company Profile
Link Pharma Chem, incorporated on December 28, 1984 is a manufacturer of thionyl chloride.
The company manufactures thionyl chloride and other inorganic chemical intermediates at its plants located in the Baroda and Ankleshwar districts of Gujarat with an installed capacity of 2,100 TPA. In FY08, the company received an international grant from United Nations Industrial Development Organization of Rs 7.7 million for phasing out a carbon tetra chloride product as raw material, which was implemented. The company plans to develop the acquired land in the Baroda district and has purchased a 10,800 sq. m. plot with RCC building of approximately 50,000 sq. ft. constructed area from DRT Ahmedabad for Rs 14 million for diversification projects.
Link Pharma Chem has, over the years, followed the best business practices. The company believes that good corporate governance is essential to achieve long-term corporate goals and to enhance stakeholders' value. In this pursuit, the company is committed to conducting business in accordance with the highest legal and ethical standard, superior product quality and services to its customers. All employees are bound by a code of conduct, which sets forth the company's policies on important issues, including relationship with customers, vendors and the government.
Business areas of the company:
The company manufactures thionyl chloride and other inorganic chemical intermediates at its plants located in the Baroda and Ankleshwar districts of Gujarat with an installed capacity of 2,100 TPA.
| 1 Day |
|
-0.54% |
| 1 Week |
|
-0.27% |
| 1 Month |
|
+8.36% |
| 3 Month |
|
+2.64% |
| 6 Month |
|
+63.13% |
| 1 Year |
|
+157.49% |
| 2 Year |
|
+229.91% |
| 5 Year |
|
+179.71% |
| 9 years | 2012-03 | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | |
| Return on Equity (%) | 5.16 | 2.88 | 4.97 | -23.07 | 6.83 | 2.58 | 12.34 | 6.53 | 8.71 | |
| Return on Capital Employed (%) | 9.39 | 9.74 | 9.32 | -8.74 | 9.83 | 9.26 | 15.38 | 10.31 | 12.87 | |
| Return on Assets (%) | 2.18 | 1.20 | 2.01 | -8.35 | 2.70 | 1.31 | 6.61 | 3.74 | 5.14 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Shh. Funds | 10 | 10 | 11 | 8 | 9 | 9 | 10 | 10 | 11 | |
| Non Curr. Liab. | 4 | 5 | 6 | 8 | 1 | 2 | 3 | 3 | 4 | |
| Curr. Liab. | 10 | 9 | 10 | 9 | 7 | 7 | 4 | 5 | 3 | |
| Minority Int. | ||||||||||
| Equity & Liab. | 23 | 25 | 26 | 26 | 18 | 17 | 17 | 18 | 19 | |
| Non Curr. Assets | 16 | 16 | 17 | 18 | 10 | 10 | 11 | 11 | 10 | |
| Curr. Assets | 7 | 9 | 10 | 8 | 7 | 7 | 7 | 7 | 9 | |
| Misc. Exp. not W/O | ||||||||||
| Total Assets | 23 | 25 | 26 | 26 | 18 | 17 | 17 | 18 | 19 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Net Sales | 18 | 16 | 24 | 18 | 12 | 16 | 24 | 25 | 25 | |
| Other Income | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | |
| Total Income | 18 | 17 | 24 | 18 | 15 | 16 | 24 | 25 | 26 | |
| Total Expenditure | -16 | -14 | -21 | -18 | -13 | -14 | -21 | -22 | -23 | |
| PBIDT | 2 | 2 | 3 | -1 | 3 | 2 | 3 | 2 | 3 | |
| Interest | -1 | -1 | -1 | -1 | -1 | -1 | -1 | 0 | 0 | |
| Depreciation | 0 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | |
| Taxation | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
| Exceptional Items | ||||||||||
| PAT | 1 | 0 | 1 | -2 | 1 | 0 | 1 | 1 | 1 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Cash Fr. Operatn. | 3 | -1 | 1 | 5 | -4 | 2 | 4 | 1 | 3 | |
| Cash Fr. Inv. | -2 | -1 | -1 | -3 | 9 | -1 | -1 | -1 | -2 | |
| Cash Fr. Finan. | -2 | 2 | 0 | -1 | -6 | -1 | -3 | 0 | 1 | |
| Net Change | -1 | 0 | 0 | 1 | -1 | 0 | 0 | 2 | ||
| Cash & Cash Eqvt | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 |
|
Mon, 05 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
|
||||||||||||||
|
Mon, 05 Jul 2021
Shareholding for the Period Ended June 30 2021 Link Pharma Chem Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here |
||||||||||||||
|
Sat, 03 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Compliance Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended June 30 2021. |
| Fri, 23 Jul 2021 |
Stock Underperforming Sectoral Index in both 1 Week and 3 Month
|
Both SRS And ARS Above Zero
|
NR 4
|
| Thu, 22 Jul 2021 |
Decreasing Relative Strength - Benchmark index
|
|
Both SRS And ARS Above Zero
|
Equities
M.F.
Sectors